Is nystatin appropriate for treating a urinary yeast infection (positive urine potassium hydroxide smear) when fluconazole is unavailable?

No, nystatin does NOT have adequate coverage for urinary yeast infections

Nystatin is not appropriate for treating urinary tract candidiasis because it does not achieve therapeutic urinary concentrations and is not recommended by IDSA guidelines for this indication. 1

Why Nystatin Fails for Urinary Candidiasis

Pharmacokinetic Limitations

• Nystatin is poorly absorbed systemically when given orally, which means it cannot reach therapeutic levels in urine 2
• The drug is only mentioned in IDSA guidelines for oropharyngeal candidiasis (oral thrush), not urinary infections 1
• While nystatin shows good in-vitro activity against Candida species 3, 4, this laboratory finding is irrelevant for urinary infections where the drug cannot reach the site of infection

Guideline-Based Alternatives When Fluconazole Unavailable

The 2016 IDSA Candidiasis Guidelines provide clear alternatives 1:

For Candida Cystitis (bladder infection):

• First-line alternative: Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days (strong recommendation)
• Second-line alternative: Oral flucytosine 25 mg/kg four times daily for 7–10 days (for fluconazole-resistant C. glabrata)
• Bladder irrigation option: Amphotericin B deoxycholate 50 mg/L sterile water daily for 5 days (weak recommendation, for resistant species)

For Candida Pyelonephritis (kidney infection):

• Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days with or without flucytosine (strong recommendation)
• Flucytosine monotherapy 25 mg/kg four times daily for 2 weeks could be considered (weak recommendation)

Critical Management Steps

Before Considering Antifungal Therapy

1. Remove indwelling bladder catheter if present (strong recommendation) 1
2. Determine if treatment is actually needed - most asymptomatic candiduria does NOT require treatment 1, 5

High-Risk Patients Requiring Treatment

Treatment is indicated ONLY for 1:

• Neutropenic patients
• Very low-birth-weight infants (<1500 g)
• Patients undergoing urologic procedures
• Symptomatic cystitis or pyelonephritis

Species-Specific Considerations

• C. albicans and fluconazole-susceptible species: Fluconazole remains first choice when available
• C. glabrata (fluconazole-resistant): Amphotericin B or flucytosine 1
• C. krusei: Amphotericin B deoxycholate 1

Common Pitfalls to Avoid

1. Do not use nystatin for urinary infections - it's ineffective regardless of in-vitro susceptibility
2. Do not treat asymptomatic candiduria in most patients - it represents colonization, not infection 1, 5
3. Do not use echinocandins (caspofungin, micafungin, anidulafungin) - they do not achieve adequate urinary concentrations 5, 2
4. Do not use itraconazole, voriconazole, or posaconazole - insufficient urinary levels 5

Practical Algorithm When Fluconazole Unavailable

1. Confirm treatment is needed (symptomatic infection or high-risk patient)
2. Remove catheter if feasible
3. Check species identification and susceptibility if available
4. For most cases: Use amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily
5. For C. glabrata resistant cases: Add or substitute flucytosine
6. Duration: 1–7 days for cystitis, up to 2 weeks for pyelonephritis
7. Monitor: Renal function (amphotericin B nephrotoxicity), CBC (flucytosine bone marrow suppression)

The evidence is unequivocal: nystatin has no role in treating urinary candidiasis due to inadequate urinary drug levels, and amphotericin B deoxycholate or flucytosine are the appropriate alternatives when fluconazole cannot be used 1, 5, 2.